Product Details

Ridgeback announced that the US Food and Drug Administration (FDA) has approved the ind application for oral antiviral compound eidd-2801. The FDA's move allows Ridgeback to launch clinical trials of eidd-2801 in humans in the United States.

Eidd-2801 is an oral bioavailable form of highly effective ribonucleoside analogues, which can inhibit the replication of a variety of RNA viruses. The animal studies of two different coronaviruses showed that eidd-2801 could improve lung function, reduce weight loss and reduce the amount of virus in the lung.

Application
EIDD-2801 is the isopropylester prodrug of N4-hydroxycytidine. With improved oral bioavailability in non human primates, it is hydrolyzed in vivo, and distributes into tissues where it becomes the active 5'-triphosphate form. The active drug incorporates into the genome of RNA viruses, leading to an accumulation of mutations known as viral error catastrophe. 

COA

Our Company

Q1:Will you supply samples for testing?
A: Free samples for the quality evaluation for most products, customers only need to undertake the shipping fee for delivery the samples to your door.

Q2:What's your MOQ?
A: For the high value product, our MOQ starts from 10g,100g and 1kg.

Q3:Which kind of payment terms do you accept?
A: Proforma invoice will be sent first after confirmation of order, enclosed our bank information. Payment by T/T, Western Union or Alibaba). Bulk order by T/T or L/C.

Q4:How about your delivery time?
A: Generally, it will take 3 to 5 days after receiving your advance payment.

Q5:How do you treat quality complaint?
A:First of all, our quality control will reduce the quality problem to near zero. If there is a real quality problem caused by us, we will send you free goods for replacement or refund your loss.